Making CRISPR gene editing safer for therapeutic applications
Researchers have discovered a Cas9 mutant that increases the fidelity of CRISPR gene editing and avoids off-target hits. CRISPR has been widely recognized as a powerful tool for gene editing but the risk of off-target effects remains a major concern and limits the potential of CRISPR gene editing as an effective and reliable therapeutic option. Now, a team of researchers led by a group from Wenzhou Medical University (China) have demonstrated that the fidelity of CRISPR gene editing can be improved by mutating the Cas9 enzyme. This could lead to a safer therapeutic strategy for CRISPR gene editing than the...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
